Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Animal cell – per se – expressing immunoglobulin – antibody – or...
Patent
1995-06-05
1999-06-29
Stucker, Jeffrey
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Animal cell, per se, expressing immunoglobulin, antibody, or...
435235, 435236, 4242041, 5303883, 5303894, C07K 1600
Patent
active
059168064
ABSTRACT:
The present invention provides a non-infectious immunotherapeutic containing retroviral particles devoid of outer envelope proteins or containing selected antigens isolated from a retrovirus. There is also provided a vaccine effective against HIV. In one aspect, the immunogen is useful for immunizing an individual previously infected by a retrovirus including HIV, so as to induce immunoprotective factors protective against progression of the infection. In another aspect, the vaccine is useful for vaccinating an individual not previously infected with HIV in order to prevent subsequently acquired infection. In another aspect, there is provided a method of rendering a viral immunogen non-infectious. The immunogen may also be used to produce antibodies for passive immunotherapy, alone or in conjunction with active immunotherapy, in individuals infected with a retrovirus, including HIV, preferably those individuals exhibiting low levels of antibodies to retroviral gene products other than the outer envelope.
REFERENCES:
patent: 4086134 (1978-04-01), Jarrett
patent: 4591505 (1986-05-01), Prince
patent: 4716102 (1987-12-01), Levy
Baum, "The search for vaccines," Chem. & Engr. News 65:27-34 (1987).
Cease et al., "Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide," Proc. Natl. Acad. Sci. 84:4249-4253 (1987).
Chan et al., "Induction of anti-HIV neutralizing antibodies by synthetic peptides," The EMBO Journal 5:3065-3071 (1986).
Chang et al., Nature 315:151-154 (1985).
Defendi et al., "Oncogenicity by DNA Tumor Virsues: Enhancement after Ultraviolet and Cobalt-60 Radiations," Science 157:703-705 (1967).
Fauci, Proc. Natl. Acad. Sci. USA 83:9278-9283 (1986).
Fischer, "Therapeutic Uses of Intravenous Gammaglobulin for Pediatric Infections," Pediatric Clinics of North America 35:517-533 (1988).
Koff et al., Science 241:426-432 (1988).
Kramer et al., Science 231:1580-1584 (1986).
Marx et al., "Prevention of Simian Acquired Immune Deficiency Syndrome with a Formalin-Inactivated Type D Retrovirus Vaccine," J. of Virology 60:431-435 (1986).
Marx, "Problems with AIDS Vaccines," Science 228:162-165 (1985).
Newmark, "Problems with AIDS Vaccines," Nature 324:304-305 (1986).
Quinnan et al., Transfusion 26(3):481-483 (1986).
Robert-Guroff et al., "In Vitro Generation of an HTLV-III Variant by Neutralizing Antibody," J. of Immunology 137:3306-3309 (1986).
Salk, Nature 327:473-476 (1987).
Sarngadharan, Cancer Res. (Supplemental) 45:4574-4577 (1985).
Sternberg et al., "Predicition of antigenic determinantes and secondary structures of the major AIDS virus proteins," FEBS Letters 218:231-237 (1987).
Zagury et al., Nature 326:249-250 (1987).
Quinnan, et al, 1986, "Inactivation of human . . . " Transfusion 26(5): 481-483.
Marx, et al, 1986, "Prevention of simian acquired . . . " J. Virology 60(2): 431-435.
Spire, et al, 1985, "Inactivation of lymphadenopathy associated . . . " Lancet, Jan. 26, 1985, 188-189.
Haynes, 1993, "Scientific and Social . . ." Science 260: 1279-1286.
Fox, et al, 1994, "No winners against AIDS"Biotechnology 12:128.
Carlo Dennis J.
Salk Jonas
Stucker Jeffrey
The Immune Response Corporation
LandOfFree
Prevention and treatment of retroviral disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prevention and treatment of retroviral disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prevention and treatment of retroviral disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1375175